| Target Price | $9.18 | 
| Price | $5.36 | 
| Potential | 
      
            
    
      
    
  71.27%
     register free of charge | 
| Number of Estimates | 9 | 
| 9 Analysts have issued a price target AbCellera Biologics Inc 2026 .
        The average AbCellera Biologics Inc target price is $9.18.
        This is 
       
    
      
    
  71.27%
     register free of charge 
                $17.85 
    
      
    
  233.02%
     register free of charge 
                $5.05 
    
      
    
  5.78%
     register free of charge | |
| A rating was issued by 14 analysts: 12 Analysts recommend AbCellera Biologics Inc to buy, 2 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
| Analyst Estimates: Analysts believe that the AbCellera Biologics Inc stock has an average upside potential 2026 of 
       
    
      
    
  71.27%
     register free of charge | 
| Dec '24 | 2025 Estimates | |
|---|---|---|
| Revenue Million $ | 28.83 | 33.73 | 
| 24.19% | 17.00% | |
| EBITDA Margin | -776.69% | -716.45% | 
| 38.80% | 7.76% | |
| Net Margin | -564.90% | -550.87% | 
| 46.74% | 2.48% | 
11 Analysts have issued a sales forecast AbCellera Biologics Inc 2025 . The average AbCellera Biologics Inc sales estimate is
This results in the following potential growth metrics:
5 Analysts have issued an AbCellera Biologics Inc EBITDA forecast 2025. The average AbCellera Biologics Inc EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
11 AbCellera Biologics Inc Analysts have issued a net profit forecast 2025. The average AbCellera Biologics Inc net profit estimate is
This results in the following potential growth metrics and future Net Margins:
| Dec '24 | 2025 Estimates | |
|---|---|---|
| Earnings Per Share $ | -0.55 | -0.62 | 
| 7.84% | 12.73% | |
| P/E | negative | |
| EV/Sales | 31.09 | 
11 Analysts have issued a AbCellera Biologics Inc forecast for earnings per share. The average AbCellera Biologics Inc EPS is
This results in the following potential growth metrics and future valuations:
AbCellera Biologics Inc...
| Analyst | Rating | Action | Date | 
|---|---|---|---|
| Stifel | Locked ➜ Locked | Locked | Aug 08 2025 | 
| Keybanc | Locked ➜ Locked | Locked | Jul 14 2025 | 
| Truist Securities | Locked ➜ Locked | Locked | May 16 2025 | 
| Keybanc | Locked ➜ Locked | Locked | Apr 16 2025 | 
| Benchmark | Locked ➜ Locked | Locked | Mar 03 2025 | 
| Stifel | Locked ➜ Locked | Locked | Feb 28 2025 | 
| Keybanc | Locked ➜ Locked | Locked | Jan 08 2025 | 
| Analyst Rating | Date | 
|---|---|
| Locked 
            Stifel:
             Locked ➜ Locked | Aug 08 2025 | 
| Locked 
            Keybanc:
             Locked ➜ Locked | Jul 14 2025 | 
| Locked 
            Truist Securities:
             Locked ➜ Locked | May 16 2025 | 
| Locked 
            Keybanc:
             Locked ➜ Locked | Apr 16 2025 | 
| Locked 
            Benchmark:
             Locked ➜ Locked | Mar 03 2025 | 
| Locked 
            Stifel:
             Locked ➜ Locked | Feb 28 2025 | 
| Locked 
            Keybanc:
             Locked ➜ Locked | Jan 08 2025 | 
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


